![]() |
The new stock research experience is built to take
advantage of the latest browser technology.
RELATED RESOURCES |
The current research page will be phased out by summer.
Click Use New Research and get the same data you use today,
plus new tools and insights.
Snapshot:BGNEBEIGENE LTD171.27
|
|
Company ProfileLog in for more informationBeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat… ![]() BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. ![]() Sector (GICS®)Health CareIndustry (GICS®)BiotechnologyEnvironmental, Social & Governance Summary (ESG)![]() ESG ratings enable you to leverage independent ESG research to evaluate how companies are managing ESG risks and addressing ESG opportunities. Learn more About Environmental, Social & Governance Summary (ESG)MSCI ESG RatingsEnvironmental, Social, and Governance (ESG) Flags: MSCI Ratings publishes Environmental, Social and Governance (ESG) ratings on over 6,000 companies worldwide. These ratings provide an independent assessment of the sustainable investment value of public companies. The ESG Ratings model is based on a carefully crafted and applied list of KeyMetrics® that result in an overall ESG concern level as expressed by Red (High Concern), Yellow (Average Concern), and Green (Low Concern) flags. Unlike traditional ESG risk models, MSCI's rating methodology is designed to identify risks most likely to affect equity valuations. Specifically, these ratings reflect actual corporate behaviors rather than policies or affirmations of intent to adhere to best ESG practices. Further, unlike other models with evenly weighted metrics, we assign context-sensitive relative weightings to our key metrics, based on market, regional, ownership or sector differences. Individual company scores are then assigned as a percentile rank, ranging from 1 (worst ranked) to 100 (best) on the basis of these KeyMetrics® and then converted to the Red, Yellow or Green flag designation. Company Reports: In addition to a company's overall risk rating, ESG reports also include an industry rating based on a comparison between the company's risk levels in each ESG component area relative to its industry peers. Further, the ESG analysis serves as a summary of behavioral events that contributed to the company's overall risk level. Full Time Employees: 8,200
Executives
www.beigene.com
55 Cambridge Parkway, Suite 700W 1-781-801-1800 |
Analyst OpinionsThe Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More.... Log in to view the Equity Summary Score for BGNE
Log in
to view all Analyst Opinions for BGNE
Research Reports
Company Research Highlights® Report (PDF)
This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.
Compustat ® Company Report
This generated report* has historical data on financials with interactive charts, technical indicators, and five-year peer comparison trend charts.
*Generated reports are built dynamically when you select them. Reports may not be available for some symbols. Select the link to check availability for this symbol.
BGNE Industry Comparison:Vs. Biotechnology |